Cibus (CBUS) Depreciation & Amortization (CF) (2016 - 2026)
Cibus (CBUS) posted Depreciation & Amortization (CF) of $1.3 million for Q4 2025, down 8.87% sequentially from $1.4 million in Q3 2025, and down 21.48% YoY from $1.6 million in Q4 2024.
Cibus (CBUS) Depreciation & Amortization (CF) (2016 - 2026) Analysis & Trends
Cibus has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $1.3 million in Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 21.48% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (down 13.65% YoY) and the FY2025 annual result came in at $5.9 million, down 13.65% from the prior year.
- Depreciation & Amortization (CF) slipped to $1.3 million in Q4 2025 per CBUS's latest filing, from $1.4 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.8 million in Q4 2023 and troughed at $370000.0 in Q1 2022.
- A 5-year average of $1.1 million and a median of $999500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) slumped 36.75% in 2022, then soared 383.51% in 2023.
- Over 5 years, Depreciation & Amortization (CF) stood at $562000.0 in 2021, then slumped by 33.1% to $376000.0 in 2022, then jumped by 383.51% to $1.8 million in 2023, then slipped by 9.35% to $1.6 million in 2024, then dropped by 21.48% to $1.3 million in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.3 million, $1.4 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 681,000.00 |
| Jun 30, 2026 | 681,000.00 |
| Dec 31, 2025 | 1.29 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.42 Mn |
| Sep 30, 2025 | 1.42 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.63 Mn |
| Mar 31, 2025 | 1.63 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Dec 31, 2023 | 1.82 Mn |